InvestorsHub Logo
Followers 8
Posts 1427
Boards Moderated 0
Alias Born 06/30/2016

Re: fabius post# 20096

Monday, 11/07/2016 9:46:38 AM

Monday, November 07, 2016 9:46:38 AM

Post# of 38634
Fabius...I totally agree. that was my original point. the same game will still be played just at a different floor. but that's the critical point to keep in mind when stating where we will be in 6 months or a year. while we should hit a high of say $6 to maybe even $8 depending on the deal. the real question is where does the floor end up? once Institutions do get in. they play only based on earnings. so then we wont see much appreciation in price until they actually deliver. if we have a bad QE you see the price nose dive. if you see the company meet expectation you see a gradual increase in value and appreciation. the speculative value goes out the window. they want to see only earnings. Hence why I try and bring what I think is a balanced thought to that side of the table. when people throw out they expect earnings of 20 to 24 million on Seroquel. I ask how? Seroquel is a 1.2 billion dollar drug without generic pricing. once generics hit the revenue goes down. Focalin was a 740 million sales drug and we have 35% market cap with 2 doses and our income is 600k a quarter. while I admit we arent selling all doses , if we were that may give us what 1.5 million a QE ? so I would expect Seroqeul to bring in slightly more because we are not only profit sharing but manufacturing at cost plus BUT we still need to be competitive which is why I say we're likely to see 2.5 a QE. which is still good. BUT if the company is going to trade on earnings once the institutions get here we need to look at all this to fairly assess the company. Now the point of a forum is debate. so, tell me what I am missing? I don't take offense at anyone for having a differing opinion. Podras is a worth BILLIONS. but sadly that has been shown to have zero effect for a speculative valuation. otherwise we all know its just a matter of getting the patent in hand and we still haven't seen a pop that is sustained. so clearly that approval is built in to our price today. so when Institutions get here, they're going to want to see earnings. well, then thats still realistically 3 to 4 years away depending on the required tests.